Mannkind

Management is actually showing prudence. Hopping into bed with a Chinese partner might solve an immediate cash need but would risk the IP long term. Chinese companies structure deals which allow them to get hold of the intellectual property so they can clone it/ steal it. All of this is done with the government of China turning the other way.

A major player in global pharma will have the resources to pursue the Chinese when they attempt to commandeer the drug. A protracted IP infringement suit in China would cripple a company the size of MannKind.

All IMO.

Swing